AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

AbbVie Inc.NYSE: ABBV

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents broadly unchanged from a year ago

Cash & equivalents stood at $6.57B at the end of Q2 FY2026, up 1.6% from a year earlier and down 30.1% from the prior quarter. Over 3 fiscal years it compounded at -17.2% a year.

Context

  • Cash & equivalents amounted to 4.9% of total assets at the end of Q2 FY2026, up 0.1 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +1.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6.57B-30.1% QoQ
Last fiscal yearDec 2025
$5.23B-5.3% YoY
Year agoJun 2025
$6.47B+1.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.6%——
1 year-5.3%——
3-year CAGR-17.2%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
5.23B USD
Year-over-year change
-5.3%
4-year CAGR
-14.4%

Cash & Equivalents vs competitors

How ABBV compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +1.6% is the 4th highest of 10, against a peer median of -7.2%.
  • Cash & equivalents amounts to 4.9% of total assets for ABBV, versus a peer median of 6.2%.
ABBV Competitors
Cash & Equivalents for ABBV and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JNJJohnson & JohnsonSep 2026$16.91B USD-7.2%+15.2%8.6%
AMGNAmgen Inc.Jun 2026$13.99B USD+74.3%+6.2%14.6%
LLYEli Lilly and CompanyJun 2026$8.89B USD+163.3%+51.3%6.2%
BMYBristol-Myers Squibb CompanyJun 2026$8.72B USD-30.8%+3.8%10.0%
AZNAstraZeneca PLCSep 2026$7.92B USD-2.7%-2.5%6.6%
NVSNovartis AGJun 2026$7.62B USD+14.4%+15.0%6.2%
MRKMerck & Co., Inc.Jun 2026$6.85B USD-14.5%+4.7%5.3%
ABBVAbbVie Inc.Jun 2026$6.57B USD+1.6%-17.2%4.9%
GSKGSK plcJun 2026£3.09B GBP-37.4%-3.1%5.0%
PFEPfizer Inc.Jun 2026$976M USD-40.4%+40.0%0.5%
Peer median (excluding ABBV) —-7.2%+6.2%6.2%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents9.75B9.2B12.81B5.52B5.23B
Short-term Investments84M28M2M31M28M
Net Receivables9.98B11.25B11.16B10.92B12.59B
Inventory3.13B3.58B4.1B4.18B4.95B
Other Current Assets226M4.4B4.93B4.93B6.27B
Total Current Assets27.93B28.46B33B25.58B29.06B
Property, Plant & Equipment (Net)5.11B4.94B4.99B5.13B6.37B
Goodwill32.38B32.16B32.29B34.96B35.64B
Intangible Assets75.95B67.44B55.61B60.07B52.64B
Long-term Investments277M241M304M279M299M
Tax Assets00000
Other Non-current Assets4.88B5.57B8.51B9.14B9.95B
Total Non-current Assets118.6B110.34B101.71B109.58B104.9B
Total Assets146.53B138.81B134.71B135.16B133.96B
Account Payables2.88B2.93B3.69B2.95B3.59B
Short-term Debt12.67B4.3B7.19B6.8B8.75B
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities17.85B20.93B25.16B27.01B25.63B
Total Current Liabilities35.19B29.54B37.84B38.75B43.29B
Long-term Debt64.16B59.12B52.17B60.34B59.61B
Deferred Tax Liabilities8.98B8.69B8.63B7.63B7.96B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities22.02B23.4B24.91B24.38B25.62B
Total Non-current Liabilities95.9B91.98B86.47B93.05B93.9B
Total Liabilities131.09B121.52B124.31B131.8B137.19B
Common Stock18M18M18M18M18M
Retained Earnings3.13B4.78B(1B)(7.9B)(15.49B)
Accumulated OCI(2.9B)(2.2B)(2.31B)(1.93B)(1.14B)
Other Stockholders Equity00000
Minority Interest28M33M37M39M42M
Total Equity15.44B17.29B10.4B3.36B(3.23B)
Total Debt77.58B64.19B60.12B67.84B69.07B
Net Debt67.83B54.99B47.31B62.32B63.84B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.